Axsome Therapeutics (AXSM) Total Debt Growth (5y) (2020 - 2026)
Axsome Therapeutics (AXSM) Total Debt Growth (5y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Axsome Therapeutics | 12.28 Bn | 11.98 Bn | 176.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.56% |
| Dec 31, 2025 | 21.46% |
| Sep 30, 2025 | 18.28% |
| Jun 30, 2025 | 44.26% |
| Mar 31, 2025 | 56.69% |
| Dec 31, 2024 | 55.41% |
| Sep 30, 2024 | 34.86% |
| Jun 30, 2024 | 56.93% |
| Mar 31, 2024 | 57.08% |
| Dec 31, 2023 | 92.88% |
| Sep 30, 2023 | 88.55% |
| Jun 30, 2023 | 84.92% |
| Mar 31, 2023 | 75.57% |
| Dec 31, 2022 | 58.76% |
| Sep 30, 2022 | 58.49% |
| Jun 30, 2022 | 58.39% |
| Mar 31, 2022 | 37.99% |
| Dec 31, 2021 | 38.19% |
| Sep 30, 2020 | 34.06% |